HomeAI · summaries
Storia in 4 fonti
Celcuity got its cancer drug approved. Then its stock dipped
Celcuity's Revtorpyk wins FDA approval but won't launch until late Q3, sending shares down 14% as analysts expected a faster rollout.
Confronto fonti
4 prospettive sulla stessa storiaTimeline cronologica
- ·
endpoints.news
Celcuity wins approval for breast cancer drug Revtorpyk
Celcuity's Revtorpyk wins FDA approval for use in HR+/HER2- breast cancer without a PIK3CA mutation.
- ·
fiercepharma.com
With FDA approval for its breast cancer blockbuster hopeful, Celcuity could ‘belong in the hands’ of a Big Pharma
The FDA has approved a new | The FDA has approved a new small molecule inhibitor from Celcuity with blockbuster potential that could become a new standard-of-care for patients…
